Clinical Trial

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC). Study objectives: Primary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT). Secondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-03-08; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2022-09-28
Trial Details
NCT Number NCT05284552
Lead Sponsor University Hospital, Linkoeping
Collaborators: Region Jönköping County, Västervik Hospital, Vastra Gotaland Region, Region Västerbotten
Conditions Epithelial Ovarian Cancer
Enrollment 40 participants
Start Date 2022-07-12
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-11